Strongbridge Biopharma plc Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Thursday, September 17, 2020
Information
Tags: 
Finance, Economy, Money, Portnoy, Securities fraud, Short, Investor
Geotags: 
Los Angeles, Us
Organisation: 
PORTNOY LAW
Summary
Key Points: 
  • LOS ANGELES, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • A press release was issued by Strongbridge on September 8th, 2020, entitled "Strongbridge Biopharma's Recorlev successful in Cushing's syndrome study."
  • The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing.


Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. The investigation concerns whether Strongbridge and certain of its directors and/or officers have engaged in securities fraud or other unlawful business practices.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

A press release was issued by Strongbridge on September 8th, 2020, entitled "Strongbridge Biopharma's Recorlev successful in Cushing's syndrome study."  While this press release reported "positive results from [Strongbridge's] 44-subject Phase 3 clinical trial, LOGIC, evaluating Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome, treatment-emergent adverse events," that included "nausea (29%), hypokalemia (28%), headache (21%), hypertension (19%) and diarrhea (15%)," were also disclosed in this press release.

Strongbridge's stock price fell $0.71 per share, or 20.11%, on this news, to close at $2.82 per share on September 8, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

 

Primary Logo
Copyright: 
2020 GlobeNewswire, Inc.. All Rights Reserved.